Core Viewpoint - The A-share market experienced a significant surge in brain-computer interface (BCI) stocks, driven by Elon Musk's announcement regarding Neuralink's plans for large-scale production in 2026, indicating a shift towards commercialization of BCI technology [1][2][4] Group 1: Market Performance - On the first trading day of 2026, multiple BCI-related stocks hit their daily limit, with companies like Beikang rising by 30% and others such as Sanbo Brain Science and DiNaiKe increasing by 20% [1][2] - A total of 52 BCI concept stocks closed higher, with over 40 stocks reaching their daily limit, showcasing strong market enthusiasm [2] Group 2: Technological Advancements - Neuralink's announcement includes plans for a streamlined and automated surgical process for BCI devices, which could reduce the invasiveness of traditional methods [2][4] - The company has successfully implanted its BCI devices in 12 individuals, with a total usage time exceeding 15,000 hours, demonstrating the technology's potential for controlling physical devices [3] Group 3: Industry Outlook - The BCI market is projected to exceed $10 billion by 2030, with long-term estimates suggesting it could reach approximately $124 billion by 2034, driven by advancements in technology and integration with AI and robotics [6] - The Chinese government has identified BCI as a future industry in its "14th Five-Year Plan," indicating strong policy support for the sector [6] Group 4: Competitive Landscape - Companies like Qiangnao Technology are emerging as leaders in non-invasive BCI solutions, with a focus on various applications such as insomnia and autism intervention [5] - The market for non-invasive BCI products currently holds an 82% share globally, indicating a significant opportunity for growth in this segment [5]

Summary of Neural Interface Industry Conference Call Industry Overview - The conference call focused on the neural interface industry, particularly the advancements made by Neuralink and the current state of domestic companies in this field [1][2]. Key Points and Arguments Neuralink's Innovations - Neuralink has significantly improved the efficiency of its brain-machine interface (BMI) devices, reducing the implantation time from 5-10 seconds to 5 seconds and the overall surgery time from several minutes to just a few minutes [1]. - The company has drastically lowered costs through in-house development, with the cost of the fixture head decreasing from $10,000 to $500, and the electrode costs also significantly reduced, laying the groundwork for large-scale applications [1][3]. - Neuralink's electrode design includes over 100 electrodes, each with 8 channels, totaling 1,024 channels, enhancing clinical application effectiveness [3]. Domestic Competitors - Domestic companies, such as Ladder Technology, are conducting clinical trials but lag behind Neuralink in electrode quantity and automation levels, with lower yield rates and higher costs [1][4]. - The current cost of domestic electrodes is approximately 30,000 RMB, with surgery costs ranging from 300,000 to 400,000 RMB, highlighting the need for improved production processes and yield rates [4]. Technological Advantages - Neuralink's devices are equipped with high-precision electron microscopes, enabling real-time monitoring of brain movements, which is crucial for safe and precise implantation [5][6]. - The automation level of Neuralink's devices allows for rapid surgeries, potentially reducing costs significantly in the future [6]. Challenges in Domestic Development - The domestic neural interface technology is primarily semi-invasive, suitable for rehabilitation but limited in treating neurodegenerative diseases [7]. - Domestic companies face challenges in achieving high yield rates for electrodes, which currently stand at about 30%, and need to improve manufacturing processes to lower costs [10][15]. Government Support and Policies - The government plans to launch a key support program for the neural interface industry in the second half of 2025, with each province reporting one key support entity to avoid disordered competition and resource waste [2][21]. - A collaborative effort among seven ministries aims to unify resources and focus on specific areas such as electrode and chip development, enhancing overall research efficiency [22]. Future Outlook - The domestic neural interface industry is expected to grow, but companies must overcome significant challenges related to technology, cost, and yield rates [12][13]. - The government is expected to release new standards for neural interface medical devices in the first half of 2025, which will help regulate the industry [23]. Conclusion - Neuralink's advancements in technology and cost reduction position it as a leader in the neural interface industry, while domestic companies are making progress but still face substantial hurdles. Government support and regulatory frameworks will play a crucial role in shaping the future of this industry in China.

Group 1 - The brain-computer interface (BCI) sector in A-shares experienced a strong opening on January 5, with the concept index rising over 13%, making it the strongest sector of the day. Stocks within the sector saw a surge, with companies like Beiyikang hitting a 30% limit up, and others like Sanbo Brain Science and Xiangyu Medical achieving 20% limit up [1] Group 2 - Elon Musk announced a production timeline for brain-computer interface devices from Neuralink, aiming for large-scale production to start in 2026. The innovative surgical process will significantly reduce operation time from 6 hours to under 20 minutes, with 12 patients already implanted with the device, accumulating over 15,000 hours of use [4] Group 3 - The global competition in the brain-computer interface field is intensifying, with the U.S. leading in invasive and semi-invasive technologies, while China is advancing in non-invasive methods. Companies like MergeLabs and Brain Tiger Technology are at the forefront of these developments [5] Group 4 - The brain-computer interface has been included in China's "14th Five-Year Plan" as a key future industry, with goals set for technological breakthroughs by 2027 and industry strength to rank among the world's top by 2030. Policies are facilitating market entry, with companies like Xiangyu Medical targeting over 1,000 hospitals by next year [6] Group 5 - The long-term prospects for the brain-computer interface industry are viewed positively by institutions, with predictions of the global market reaching $12.4 billion by 2034 and $320 billion by 2045. Recent capital inflows into the sector indicate a strong interest in its commercial potential [6]

随着马斯克明确给出脑机接口设备的量产时间表，这一前沿赛道正从实验室的科学探索加速走向商业化落地，行业或将迎来从"医疗试验品"向"大众消费品"跨越 的关键转折点。 2026年A股开盘首日，脑机接口板块表现强势。倍益康30CM涨停，三博脑科、翔宇医疗、美好医疗、爱朋医疗、诚益通、伟思医疗等多股20CM涨停，市场资 金对脑机接口商业化前景展现出极高预期。 | 代码 | 名称 | 现价 | 涨跌幅 ▼ | 涨跌 | 换手率 | | --- | --- | --- | --- | --- | --- | | 688108 | 赛诺医疗 | 23.09 | 20.01% | 3.85 | 14.83% | | 300238 | 元 | 16.62 | 20.00% | 2.77 | 13.53% | | 300753 | 爱朋医疗 | 33.30 | 20.00% | 5.55 | 21.10% | | 301363 | 美好医疗 | 28.86 | 20.00% | 4.81 | 1.93% | | 688626 | 翔宇医疗 | 72.60 | 20.00% | 12.10 | 3.36% | | 300003 | ...

Investment Rating - Investment rating: Positive (maintained) [1] Core Insights - The brain-computer interface (BCI) technology is entering a phase of large-scale production, with gaming as a significant application area, expected to benefit continuously [3] - The integration of AI in gaming is enhancing multi-modal capabilities and innovative forms, potentially opening up new industry spaces [3] - The upcoming gaming season, with new game launches and updates to existing games, is anticipated to drive revenue growth [4] Summary by Sections Brain-Computer Interface Developments - BCI technology connects the human brain with external devices for information exchange, enabling previously disabled individuals to engage in gaming through "brain-controlled" interfaces [3] - The launch of China's first fully implanted, wireless BCI product by Shanghai Brain Tiger Technology marks a significant breakthrough in core technology [3] - Companies like 37 Interactive Entertainment and Century Huatong are actively investing in BCI-related projects, indicating a growing interest in this field [3] AI Integration in Gaming - AI is enhancing various aspects of game development, from art resource generation to core creative areas like gameplay design and narrative structure [3] - Tencent reported a 40% reduction in animation production time due to AI integration, showcasing efficiency gains [3] - The number of games utilizing generative AI on the Steam platform has increased significantly, indicating a trend towards AI-enhanced gaming experiences [3] Upcoming Gaming Season - Major game releases and updates are scheduled for January, including anniversary events and new collaborations with popular IPs [4] - The report suggests focusing on the gaming sector due to its favorable valuation and expected demand surge during the holiday season [4] - Recommended companies include Giant Network, Xindong Company, and Tencent Holdings, among others, as potential beneficiaries of this trend [4]

2026年1月5日午后，创业板新能源ETF华夏（159368）涨幅扩大至2.52%。盘面上，成分股普涨，仅4只 个股下跌，道氏技术涨停，罗博特科上涨12.20%，先导智能、富临精工等涨超6%；截至发文，创业板 新能源ETF华夏（159368）成交额达6227万元，居同类基金首位。 消息面上，埃隆·马斯克2025年12月31日通过社交平台发布重磅消息，旗下脑机接口公司Neuralink计划 于2026年启动脑机接口设备大规模量产，并同步推出全自动化外科手术流程。这一规划标志着脑机接口 技术从临床验证阶段向产业化落地迈出关键一步，也成为A股人脑工程板块的强力催化。 公司面上，12月25日，道氏技术控股子公司认购强脑科技Pre-B轮优先股完成交割，推进碳材料在脑机 接口、电子皮肤等前沿领域的应用。作为国内最早量产单壁碳纳米管的企业之一，公司单壁碳纳米管粉 体性能已与进口产品相当，也是脑机接口电极材料的关键导电增强剂。 创业板新能源ETF华夏（159368）是全市场跟踪创业板新能源指数的规模最大ETF基金。创业板新能源 指数主要涵盖新能源和新能源汽车产业，涉及电池、光伏等多个细分领域。创业板新能源ETF华夏 （159 ...

Group 1 - The brain-computer interface (BCI) sector is experiencing significant growth, with companies like Neuralink and Merge Labs leading the charge in invasive and non-invasive technologies respectively [1][2] - Neuralink plans to begin large-scale production of its BCI devices in 2026, introducing a streamlined and automated surgical process that avoids traditional invasive methods [1] - Zhejiang Qiangnao Technology Co., Ltd. is emerging as a domestic unicorn in the BCI field, focusing on non-invasive technology and aiming for an IPO in mainland China or Hong Kong by 2026 [2] Group 2 - Qiangnao Technology has formed a strategic partnership with Lingyi iTech, enhancing both companies' market competitiveness and technological capabilities in the BCI and robotics sectors [2] - The global BCI market is projected to grow to approximately $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034, driven by technological advancements and policy support [2]

Group 1 - The core viewpoint highlights the continuous catalysis in the innovative drug sector, particularly with the announcement from Elon Musk that Neuralink will start large-scale production of brain-machine interface devices in 2026, transitioning to fully automated surgical processes [1] - The first national standard for brain-machine interface medical devices in China will be implemented on January 1, 2026, laying the foundation for the standardized development of the industry [1] - The market sentiment is further catalyzed by the upcoming listing of Rebio Biotech on the Hong Kong stock market, enhancing the interest in small nucleic acid drugs that regulate pathological processes at the genetic level [1] Group 2 - Zai Lab has reached a strategic cooperation with AbbVie regarding ZG006, with an upfront payment of $100 million and a total transaction value potentially reaching $1.075 billion plus sales sharing, indicating the global value recognition of the product by multinational corporations [1] - According to Founder Securities, core assets in innovative drugs are expected to continue rising, with new opportunities emerging in small nucleic acids and in vivo CAR technologies, reflecting a long-term industry trend [1] - The innovative drug business development is seen as a value realization for China's innovative drug capabilities on the global stage, with authorized core assets expected to continue realizing value as clinical progress advances [1] Group 3 - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies on the Sci-Tech Innovation Board, tracking a representative index of 30 high-quality companies, primarily in high-growth biotech [2] - During the market rebound period from September 24, 2024, to October 31, 2025, the Sci-Tech Innovation Drug Index and the Hang Seng Hong Kong Stock Connect Innovation Drug Index recorded gains of 143.70% and 135.34% respectively, suggesting that the Sci-Tech Innovation Drug Index may help share the resilience of the Sci-Tech Innovation Board when market risk appetite increases [2]

马斯克宣布Neuralink将于2026年启动脑机接口设备大规模生产，小核酸药物领域频频出现新进展，消息面催化，创新药板块利好不断，单日涨跌幅20%的科 创创新药 ETF（589720）涨超5%。 事件催化不断，创新药板块发展加速 消息面，创新药板块利好不断。脑机接口海内外共振： 马斯克宣布Neuralink将于2026年启动脑机接口设备大规模生产，转向全自动化手术流程。国内首个 脑机接口医疗器械行业标准《采用脑机接口技术的医疗器械术语》于2026年1月1日正式实施，为行业规范化发展奠定基础。脑机接口百亿级大龙头上市预计 催化板块，强脑科技、博睿康进入pre ipo轮融资。 小核酸赛道热度提升：瑞博生物即将登陆港股市场，进一步催化市场情绪。小核酸药物从基因上游调控病理过程，拓宽传统药物治疗边界。 泽璟BD合作达成：泽璟与艾伯维就ZG006达成战略合作，首付款1亿美元，总交易金额最高达10.75亿美元+销售分成，证明产品全球价值获MNC认可。 基本面看，创新药资产估值迎持续修复，近年来国产原研药获批数量持续攀升，从肿瘤治疗到自身免疫疾病领域，创新药凭借确切的临床价值迅速占领市 场。与此同时，越来越多国产创新药通 ...

2026年A股开盘首日，脑机接口概念表现活跃。截至发稿，倍益康30CM涨停，三博脑科、翔宇医疗、美好医疗、爱朋医疗、诚益通、伟思医疗20cm 涨停，创新医疗、南京熊猫10CM涨停，博拓生物、狄耐克等涨超10%。 开源证券最新研报表示， 上述行业事件印证了脑机接口技术预计将在2026年迈向商业化，并从医疗刚需向AI应用、机器人等多领域渗透 。 Neuralink的规模化生产预期+自动化手术方案，以及Merge布局新一代超声波脑机接口技术具备双重意义。一方面，这标志着脑机接口从临 床验证阶段开始向商业化规模化阶段迈进，推动脑机接口从"医疗试验工具"到"可普及产品"的落地；另一方面，未来随着技术方案成熟度的 进一步提升，也将为Neuralink脑机接口与特斯拉Optimus人形机器人的协同应用奠定基础。 该机构进一步表示，脑机接口行业正处于技术突破、政策支持、机器人生态协同预期等多重因素驱动下的高增蓄势期，根据Precedence Research数据， 预计到2034年全球脑机接口市场规模将增长到约124亿美元 ，2025-2034年CAGR为17%。 在近期Neuralink规模化量 产预期和技术突破的催化下， ...